Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Fostemsavir Formulations in Healthy Subjects
NCT02508064Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Aug 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fostemsavir in human immunodeficiency virus infection (HIV) (11 arms), sponsored by ViiV Healthcare. Primary endpoints: Maximum observed concentration of BMS-626529, Area under the concentration-time curve from time zero to the last quantifiable concentration and 1 more. Started Aug 2015; status: completed.
02
Drugs
fostemsavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02508064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02508064.